-

DeciBio Launches Market Intelligence Portal With DeciChat, an AI Assistant Powered by DeciBio’s Proprietary Precision Medicine Research

DeciChat synthesizes thousands of data points across primary data sources to deliver deep insights into precision medicine markets instantly.

LOS ANGELES--(BUSINESS WIRE)--DeciBio Consulting (“DeciBio”), a precision medicine-focused strategy consulting and market intelligence firm, launched the DeciBio Market Intelligence Portal. The portal brings DeciBio’s Market Reports, DxBooks lab survey databases, Oncology Genomics Trackers, and Transcript Database into one subscription platform. It also introduces DeciChat, an AI assistant that performs cross-product querying and synthesis. Life science tools, diagnostics, and biopharma teams can ask a question and receive an answer drawn from across DeciBio’s research, with citations to the source data.

“Precision medicine is moving faster than traditional market research can track. And decisions that once took months of analysis now need to be made in weeks,” said Rebecca Burnham, PhD, Head of DeciBio’s Market Reports Division. “The Market Intelligence Portal and DeciChat give our clients direct access to the primary research that drives those decisions, in a form they can act on right away.”

DeciChat: One Question, Every Source

DeciChat helps teams get evidence-backed answers to the market questions behind their most important decisions, from sizing an opportunity to prioritizing markets or evaluating partners. Its AI agents search proprietary data from DeciBio’s precision medicine experts, then synthesize the findings into a single response. Each answer links back to the underlying report, dataset, or transcript, so teams can verify the numbers and insights and build on them in their own analyses.

“General-purpose AI tools are only as good as what they can find, and most precision medicine market data isn’t public,” said Andrew Stiegler, PhD, Head of DeciBio’s DxBooks Division. “DeciChat’s agents work directly on our private survey data, forecasts, and interview transcripts. Automated pipelines mean every new DxBook release, tracker update, and transcript is searchable as soon as the research is completed.”

What’s Included in the Market Intelligence Portal

The Market Intelligence Portal integrates DeciChat and all of DeciBio’s proprietary data products, including:

  • Global Market Reports: Comprehensive market assessments with market sizing, segmentation, and 5-year forecasts, plus competitive analysis and assessments of key players, technologies, drivers, and moderators. Report topics span life science tools and diagnostics, including Digital & Computational Pathology, Oncology Liquid Biopsy, Next-Generation Sequencing, Spatial Biology, Single Cell Analysis, Proteomics Tools, Clinical Oncology Biomarker Testing, Blood-Based Testing in Neurodegenerative Diseases, Bioprocessing, Cell Therapy R&D and Manufacturing, Pharma Real-World Data & Evidence, and more.
  • Snapshot Reports: Qualitative deep dives on emerging sub-segments, such as Pharma CDx Development & Commercialization, Biopharma’s Use of AI in Drug Discovery, and Precision Medicine Opportunities in Women’s Health.
  • DxBooks: Databases built from annual surveys of clinical labs:
    • NGS DxBook: Panel testing, sample types, volumes, and reimbursement across 275 US and EU labs.
    • Infectious Disease DxBook: Testing settings, assays, and vendor selection for 30 analytes across 1,000 US clinical labs.
    • Digital Pathology DxBook: Scanner and IMS usage, algorithm integration, and vendor satisfaction across 400 US and EU labs.
  • Oncology Genomics Trackers: Interactive dashboards tracking oncology genomic testing across 100 US labs (quarterly) and EU labs (semiannually), characterizing the use of genomic profiling, MRD / recurrence monitoring, and treatment response monitoring.
  • Transcript Database: 450+ searchable expert interviews with stakeholders across large and small biopharma, academic medical centers, community hospitals, reference labs, CROs, and diagnostics companies.

New editions, data releases, and transcripts are added to the portal as they are published.

Availability

The DeciBio Market Intelligence Portal is available now through enterprise subscriptions to the full DeciBio Knowledgebase, custom packages built around an organization’s priority topics, or individual product subscriptions, with DeciChat available on any plan. Existing DxBooks and Oncology Genomics Trackers subscribers will be transitioned to the portal at no extra cost. The DeciBio Market Intelligence Portal is available now. Existing DxBook and Oncology Genomics Trackers subscribers will be moved to the Portal at no extra cost. To request a demo, visit www.decibio.com/intelligence-portal or contact rebecca.burnham@decibio.com.

About DeciBio

DeciBio Consulting is a precision medicine-focused strategy consulting and market intelligence firm whose mission is to accelerate the adoption of precision medicine. DeciBio helps leadership teams across therapeutics, diagnostics, research tools, and advanced manufacturing make strategy decisions grounded in scientific, technical, and execution reality. Its data division develops market intelligence software, databases, and reports covering life science research tools and diagnostics. DeciBio serves clients ranging from startups to Fortune 500 companies from offices in Los Angeles, New York City, Oakland, and London. Learn more at decibio.com.

Contacts

Media Contact
Rebecca Burnham
rebecca.burnham@decibio.com
310.451.4510

More News From DeciBio Consulting

Worldwide Digital & Computational Pathology Market Forecasted to Grow at 12% p.a., Reaching $2.1B by 2031 – Market Report by DeciBio Consulting LLC

LOS ANGELES--(BUSINESS WIRE)--DeciBio Consulting LLC’s latest market report, “Digital & Computational Pathology Market Report 2026-2031,” states that the global digital pathology market, driven by an influx of open platforms that resolve interoperability challenges and standalone regulatory clearances that enable greater clinical adoption, is predicted to reach $2.1B by 2031. The third edition of DeciBio’s digital and computational pathology (D&CP) report takes a comprehensive look at t...

Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 27% p.a., Reaching ~$17B by 2031 – Market Report by DeciBio Consulting LLC

LOS ANGELES--(BUSINESS WIRE)--DeciBio Consulting has released the fourth edition of its Oncology Liquid Biopsy Market Report, offering updated global estimates of how liquid biopsy technologies are being applied across clinical and pharmaceutical research settings. The report draws on in-depth interviews with more than 30 experts in the field, including medical oncologists, biopharma researchers, technology providers, and other key healthcare stakeholders to capture the dynamic and evolving liq...

Europe Oncology Genomics Tracker Captures Oncologist Perspectives Across Major European Markets – Data Report by DeciBio Consulting LLC

LOS ANGELES--(BUSINESS WIRE)--A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides updated insight into how genomics technologies are being evaluated, adopted, and used across Europe’s solid tumor oncology markets. The study is based on responses from 100+ medical oncologists and offers a cross-market view of current priorities, barriers, and areas of momentum. The Europe Oncology Genomics Tracker char...
Back to Newsroom